Leukemia | Topics

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.

Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML
January 21, 2021

The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.

Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML
January 14, 2021

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.